Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines

Prognosis in patients suffering from high‐risk, refractory and relapsed germ cell tumours (GCT) often comprising of CD30‐positive embryonal carcinoma (EC) components remains poor. Thus, novel treatment strategies are warranted. The antibody‐drug conjugate (ADC) brentuximab vedotin delivers the poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönberger, Stefan, van Beekum, Cornelius, Götz, Barbara, Nettersheim, Daniel, Schorle, Hubert, Schneider, Dominik T., Casati, Anna, Craveiro, Rogerio B., Calaminus, Gabriele, Dilloo, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742680/
https://www.ncbi.nlm.nih.gov/pubmed/28941150
http://dx.doi.org/10.1111/jcmm.13344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742680/
https://www.ncbi.nlm.nih.gov/pubmed/28941150
http://dx.doi.org/10.1111/jcmm.13344

Ejemplares similares